Fausto Pocar

Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding

Retrieved on: 
Thursday, November 2, 2023
University of California, Davis, Regenerative medicine, California Institute for Regenerative Medicine, UC, Good manufacturing practice, Doctor of Philosophy, Health, BD, Medicine, CGT, Gene, Partnership, University, GMP, CIRM, Point, Patient, Fausto Pocar, POC, Pharmaceutical industry

“Our goal is to facilitate more accessible patient care production through collaboration with aligned expertise.

Key Points: 
  • “Our goal is to facilitate more accessible patient care production through collaboration with aligned expertise.
  • Both parties are interested in expanding on the point of care (POC) network model Orgenesis deploys by aligning the tools, experts, and resources needed to decentralize medical innovation.
  • “We are thrilled to see such a deserving team get support from their state to show the true value of decentralization in California,” Vered Caplan, CEO of Orgenesis commented.
  • To learn more about UC Davis and their pioneering work in the cell and gene therapy industry, please visit: https://health.ucdavis.edu/stemcellresearch/ .

CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States

Retrieved on: 
Thursday, September 21, 2023
GMP, Partnership, CGT, Health care, Research, Cell, Hospital, Patient, TILS, Leukapheresis, R, Health, Fausto Pocar, Pharmaceutical industry, Medical device

The two companies are collaborating to leverage CGT Global’s extensive network of CGT Clinics and Healthcare partnerships to expand commercialization of CGTs in California and other US locations.

Key Points: 
  • The two companies are collaborating to leverage CGT Global’s extensive network of CGT Clinics and Healthcare partnerships to expand commercialization of CGTs in California and other US locations.
  • Resources will be aligned to place technology-agnostic Octomera Mobile Processing Units & Labs (OMPULs) for leukapheresis and the production of CAR-T and TILS products.
  • The Company expects the footprint to grow as CGT Global partners with 32 hospitals today and anticipates partnering with over 200 hospitals by the end of 2024.
  • CGT Global has created a bicoastal network of CGT Clinics in the US using state-of-the-art technology and specialized training in leukapheresis.

Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

Retrieved on: 
Wednesday, September 6, 2023
Children's Hospital Los Angeles, GMP, University of California, Davis, Bauer, University, HIV, Child, Washington University in St. Louis, Johns Hopkins University, UC, Patient, CGT, Engineering, University of Southern California academics, Cell, TILS, ADA, Fausto Pocar, Pharmaceutical industry

“Gerhard is an industry pioneer with unmatched expertise.

Key Points: 
  • “Gerhard is an industry pioneer with unmatched expertise.
  • He began his time at Johns Hopkins University where he was part of the team that developed the first stem cell gene therapy for HIV.
  • “We all understand that the old methods of cell and gene therapy development and production no longer apply.
  • At Octomera, we have the network, applied experience, and passion to support drug developers as they develop and commercialize lifesaving medicines,” said Mr. Bauer.

Orgenesis Provides Business Update for Second Quarter of 2023

Retrieved on: 
Friday, August 11, 2023
University of California, Davis, Partnership, University, CGT, Marketing, Telephone, University of California, UC, Patient, MM, Growth, Security (finance), Metalmark Capital, Cryptocurrency, Pharmaceutical industry, Online shopping, Labs, Fausto Pocar

GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023.

Key Points: 
  • (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023.
  • Vered Caplan, CEO of Orgenesis, said, “We are pleased to report revenue of approximately $7.0 million for the second quarter of 2023, which reflects the ongoing rollout of our POCare platform.
  • We recently rebranded the POC Services business from Morgenesis to Octomera, following an additional investment from MM OS Holdings, L.P. (“MM”), an affiliate of Metalmark Capital Partners (“Metalmark”), a leading private equity firm.
  • Overall, we believe we have built a scalable, high margin, recurring revenue business model.”
    The complete financial results for the second quarter of 2023 are available on the Company’s website in the Company’s Form 10-Q, which has been filed with the Securities and Exchange Commission.

Orgenesis Announces Name Change of Morgenesis Business Unit to Octomera

Retrieved on: 
Tuesday, July 11, 2023
GMP, Partnership, Network, CGT, Hospital, CGMP, Investment, Patient, MM, Growth, Metalmark Capital, Metalmark, Vaccine, Cryptocurrency, Labs, Fausto Pocar

Morgenesis was originally formed in 2022 to separate Orgenesis’ existing POCare Service and supply solutions from the other operations of Orgenesis.

Key Points: 
  • Morgenesis was originally formed in 2022 to separate Orgenesis’ existing POCare Service and supply solutions from the other operations of Orgenesis.
  • A new Octomera website and rebranding will be unveiled throughout the second half of 2023.
  • The capital from the MM investment is for the continued development of POCare Centers with a focus on expanding in the US market.
  • Octomera is focused on changing the paradigm of centralized cell and gene therapy (CGT) production to produce treatments in a decentralized point of care manner.

Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis

Retrieved on: 
Tuesday, May 30, 2023
Doctor of Philosophy, Regenerative medicine, Hospital, Patient, CGT, Cell, Metalmark Capital, SCB, International Society, Fausto Pocar, Pharmaceutical industry, Medical device, Labs

GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc .

Key Points: 
  • GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc .
  • (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced that cell and gene therapy pioneer Claudia Zylberberg, PhD has been appointed as an independent board member and senior advisor of its Morgenesis LLC (“Morgenesis”) point-of-care (POCare) subsidiary.
  • As founder, board member and former CEO of Akron Bio, Dr. Zylberberg has led Akron Bio to its leadership position among makers of cGMP-compliant ancillary materials, novel products, and tools for advanced and regenerative medicines.
  • “We’re very proud to have Claudia join us to guide Morgenesis as it redefines the possibilities for delivering POCare therapies,” said Vered Caplan, CEO of Orgenesis.

Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors

Retrieved on: 
Thursday, May 18, 2023
GMP, Partnership, CGT, QC, Lentivirus, CDMO, Association de médiation sociale v Union locale des syndicats CGT, SCTbio, Quality control, Family, Vaccine, Central Europe, Labs, Fausto Pocar

The goal of the collaboration is to open new point-of-care (POCare) sites within the Czech Republic and leverage SCTbio’s GMP facility for the production of lentivirus vectors to support Morgenesis’ POCare worldwide customers, including use in CAR-T cell and gene therapies (CGTs).

Key Points: 
  • The goal of the collaboration is to open new point-of-care (POCare) sites within the Czech Republic and leverage SCTbio’s GMP facility for the production of lentivirus vectors to support Morgenesis’ POCare worldwide customers, including use in CAR-T cell and gene therapies (CGTs).
  • The POCare centers and OMPULs are designed to shorten the implementation time of new production, while offering a more cost-effective environment and enabling local scalability.
  • SCTbio brings expertise in retroviral vector GMP production with a deep knowledge of state-of-the-art manufacturing technologies and quality control (QC) methods.
  • Ludek Sojka, Chief Executive Officer at SCTbio, stated, “We are looking forward to collaborating with Orgenesis.

Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare Strategy

Retrieved on: 
Wednesday, May 10, 2023
GMP, CGT, Marketing, Government, Security (finance), Cryptocurrency, Metalmark, Fausto Pocar

(NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023.

Key Points: 
  • (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023.
  • Vered Caplan, CEO of Orgenesis, said, “We achieved revenue of approximately $7.0 million for the first quarter of 2023, which reflects the continued progress of our POCare strategy.
  • We are currently focused on the implementation of our quality systems, as well as our GMP processes at the various POCare sites.
  • We are also expanding our international management team with the support of Metalmark, our long-term partner and investor in our Morgenesis subsidiary.

Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service Subsidiary

Retrieved on: 
Wednesday, May 10, 2023
CGT, Securities and Exchange Commission of Pakistan, CGMP, Patient, DSM-IV codes, Growth, Security (finance), Metalmark Capital, Therapy, Fausto Pocar, Pharmaceutical industry, Management, Metalmark

This investment follows the previously announced investment of $30 million in November 2022.

Key Points: 
  • This investment follows the previously announced investment of $30 million in November 2022.
  • In addition, Metalmark has committed to investing up to an additional $15 million, subject to the achievement of certain milestones.
  • This additional investment will further propel our growth as we expand our global operations and add key personnel, enabling us to capitalize on the substantial demand for our POCare services.
  • Morgenesis will use the additional capital to support the development of additional POCare Centers, as well as the OMPULs in both the U.S. and international markets.

Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022

Retrieved on: 
Tuesday, March 21, 2023
University of California, Davis, University, CGT, Marketing, Telephone, UC, Patient, Investment, MOU, Pancreatectomy, Security (finance), FDA, Therapy, Pharmaceutical industry, EU, Labs, Fausto Pocar

GERMANTOWN, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the fourth quarter and year ended December 31, 2022.
  • Vered Caplan, CEO of Orgenesis, said, “I am pleased to report that revenue for the fourth quarter of 2022 increased by 98% to $13.6 million, compared to $6.9 million for the same period last year as we are progressing with the planned rollout of our POCare platform.
  • In addition to our strong revenue growth, we reduced our operating loss by 91% for the fourth quarter of 2022 versus the same period last year, which reflects our cost-effective and highly scalable business model.
  • In 2022, our subsidiary, Koligo Therapeutics, supplied Kyslecel to five medical institutes supplying total pancreatectomy - islet auto transplant (TP-IAT) cases.